ELETRIPTAN HYDROBROMIDE

N/A

Manufactured by ROERIG

13,057 FDA adverse event reports analyzed

Last updated: 2026-04-15

About ELETRIPTAN HYDROBROMIDE

ELETRIPTAN HYDROBROMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ROERIG. The most commonly reported adverse reactions for ELETRIPTAN HYDROBROMIDE include DRUG INEFFECTIVE, MIGRAINE, HEADACHE, NAUSEA, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ELETRIPTAN HYDROBROMIDE.

Top Adverse Reactions

DRUG INEFFECTIVE907 reports
MIGRAINE856 reports
HEADACHE731 reports
NAUSEA494 reports
PAIN418 reports
VOMITING328 reports
FATIGUE327 reports
MALAISE287 reports
DIZZINESS266 reports
OFF LABEL USE223 reports
ANXIETY218 reports
FEELING ABNORMAL213 reports
DYSPNOEA204 reports
INSOMNIA199 reports
CONDITION AGGRAVATED196 reports
PARAESTHESIA179 reports
SOMNOLENCE172 reports
DIARRHOEA171 reports
FALL149 reports
DRUG HYPERSENSITIVITY147 reports
DEPRESSION144 reports
ARTHRALGIA139 reports
CHEST PAIN132 reports
ASTHENIA130 reports
INJECTION SITE PAIN130 reports
PAIN IN EXTREMITY127 reports
CHEST DISCOMFORT120 reports
BACK PAIN116 reports
RECALLED PRODUCT ADMINISTERED115 reports
ABDOMINAL PAIN UPPER114 reports
HYPERTENSION108 reports
HYPOAESTHESIA107 reports
PRURITUS107 reports
WEIGHT INCREASED107 reports
SINUSITIS106 reports
MEMORY IMPAIRMENT105 reports
WEIGHT DECREASED105 reports
HYPERSENSITIVITY101 reports
PRODUCT USE IN UNAPPROVED INDICATION99 reports
MUSCLE SPASMS98 reports
ABDOMINAL PAIN94 reports
BLOOD PRESSURE INCREASED94 reports
INTENTIONAL PRODUCT MISUSE94 reports
STRESS94 reports
DRUG ABUSE93 reports
NASOPHARYNGITIS92 reports
CONSTIPATION91 reports
NECK PAIN90 reports
TREMOR90 reports
RASH89 reports
ABDOMINAL DISCOMFORT88 reports
DRUG DEPENDENCE85 reports
PYREXIA84 reports
MYALGIA82 reports
URTICARIA80 reports
PALPITATIONS78 reports
DRUG INTERACTION77 reports
PNEUMONIA76 reports
CONFUSIONAL STATE74 reports
GAIT DISTURBANCE74 reports
INJURY73 reports
VISION BLURRED72 reports
ASTHMA71 reports
COUGH71 reports
DEEP VEIN THROMBOSIS70 reports
LOSS OF CONSCIOUSNESS69 reports
SUICIDAL IDEATION69 reports
ALOPECIA68 reports
URINARY TRACT INFECTION68 reports
BRONCHITIS66 reports
HYPERHIDROSIS66 reports
PRODUCT DOSE OMISSION ISSUE65 reports
PULMONARY EMBOLISM64 reports
COVID 1963 reports
DRUG EFFECT INCOMPLETE63 reports
CEREBROVASCULAR ACCIDENT61 reports
FIBROMYALGIA58 reports
DISTURBANCE IN ATTENTION56 reports
ROAD TRAFFIC ACCIDENT56 reports
DECREASED APPETITE55 reports
MEDICATION OVERUSE HEADACHE55 reports
OVERDOSE55 reports
CONTUSION54 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE54 reports
THROAT TIGHTNESS54 reports
CONVULSION53 reports
AMNESIA52 reports
EMOTIONAL DISTRESS52 reports
ERYTHEMA52 reports
MUSCULOSKELETAL STIFFNESS52 reports
PRODUCT USE ISSUE52 reports
DRUG DOSE OMISSION51 reports
GASTROINTESTINAL DISORDER51 reports
SPEECH DISORDER51 reports
VISUAL IMPAIRMENT51 reports
ARTHRITIS50 reports
BALANCE DISORDER50 reports
DRUG INTOLERANCE50 reports
DYSPEPSIA50 reports
FLUSHING50 reports

Report Outcomes

Out of 6,943 classified reports for ELETRIPTAN HYDROBROMIDE:

Serious 52.4%Non-Serious 47.6%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female5,630 (86.7%)
Male801 (12.3%)
Unknown65 (1.0%)

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ELETRIPTAN HYDROBROMIDE?

This profile reflects 13,057 FDA FAERS reports that mention ELETRIPTAN HYDROBROMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ELETRIPTAN HYDROBROMIDE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, MIGRAINE, HEADACHE, NAUSEA, PAIN, VOMITING. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ELETRIPTAN HYDROBROMIDE?

Labeling and FAERS entries often list ROERIG in connection with ELETRIPTAN HYDROBROMIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.